Latest filingAug 31, 2026Most recent Form 4
VRXA
Veraxa Biotech AG - Post de-SPAC
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$8.26M2 buys
Total selling$00 sells
Net open-market+$8.26M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period2transactions
- P · Open-market buys · dominant2 · 100%
Activity by reported role
A joint filing can contribute to multiple roles2transactions
- Chief executive officer · dominant1 · 50%
- Director1 · 50%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeAntz Christoph RudigerOrdinary Shares · Direct
5,000Aug 27, 2026
Baumann Oliver RolfOrdinary Shares · Indirect · See Footnote
5,773,618Aug 27, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- BR+$75.0k
- AR+$7.7k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
VRXA transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| VRXA | Baumann Oliver Rolf | DIR | buy | 50.0k | $7.50M | P | — | 08/31 | 08/27 | |
| VRXA | Antz Christoph Rudiger | CEO | buy | 5.00k | $765k | P | — | 08/31 | 08/27 |
Veraxa Biotech AG - Post de-SPAC Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Veraxa Biotech AG - Post de-SPAC?
Baumann Oliver Rolf, Antz Christoph Rudiger.
When was the latest reported open-market purchase?
Baumann Oliver Rolf reported a buy on Aug 27, 2026 valued at $7.50M. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $82,650.00. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.